Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase 1 study. We report the results...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Bartlett, Nancy L., Costello, Brian A., LaPlant, Betsy R., Ansell, Stephen M., Kuruvilla, John G., Reeder, Craig B., Thye, Lim S., Anderson, Daniel M., Krysiak, Kilannin, Ramirez, Cody, Qi, Jing, Siegel, Barry A., Griffith, Malachi, Griffith, Obi L., Gomez, Felicia, Fehniger, Todd A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5757691/
https://ncbi.nlm.nih.gov/pubmed/29074501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-804641
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items